Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access

Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access

Introduction Interleukin 5 (IL-5) inhibitors are an important therapeutic advance in the management of severe, refractory, eosinophilic asthma. However, their utilisation should be targeted to maximise their benefits. This study used multisite, centralised, national data collected over 18 months to...

Full description

Bibliographic Details
Main Authors: Cathal Walsh, Michael Harrison, Richard W Costello, Roisin Adams, Desmond M Murphy, Caroline O'Leary, Christopher Schultz, Deborah Casey, Stephen Lane, Shane Doyle, Fionnuala King
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/9/1/e001341.full

Internet

https://bmjopenrespres.bmj.com/content/9/1/e001341.full

Similar Items